ResMed
919 hedge funds and large institutions have $23.9B invested in ResMed in 2025 Q2 according to their latest regulatory filings, with 118 funds opening new positions, 355 increasing their positions, 324 reducing their positions, and 76 closing their positions.
55% more first-time investments, than exits
New positions opened: 118 | Existing positions closed: 76
13% more capital invested
Capital invested by funds: $21.1B → $23.9B (+$2.82B)
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
4% more funds holding
Funds holding: 885 → 919 (+34)
10% more repeat investments, than reductions
Existing positions increased: 355 | Existing positions reduced: 324
0.97% less ownership
Funds ownership: 64.26% → 63.29% (-0.97%)
44% less call options, than puts
Call options by funds: $109M | Put options by funds: $196M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
+$146M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$78.4M |
| 3 |
Squarepoint
New York
|
+$74.3M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$64.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$60.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$353M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$130M |
| 3 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
-$116M |
| 4 |
BlackRock
New York
|
-$60.1M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$51.5M |
RMD Hedge Fund Activity: Q2 2025 in Review
919 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q2 2025, worth a combined $23.9B — up 13% from $21.1B a quarter earlier.
Buyers outnumbered sellers: 118 funds opened new RMD positions and 76 closed out — a net gain of 42 holders — while 355 added to existing stakes and 324 trimmed.
The largest buyer was Norges Bank, adding an estimated $146M. The largest seller was Morgan Stanley, cutting an estimated $353M.
- 919 institutional investors held ResMed (RMD) as of Q2 2025, up from 885 in Q1 2025.
- Funds reported $23.9B of ResMed stock for Q2 2025, up 13% quarter-over-quarter.
- 118 funds opened new ResMed positions in Q2 2025 and 76 closed out, a net change of +42 holders.
- The largest ResMed buyer in Q2 2025 was Norges Bank, an estimated $146M added.
- The largest ResMed seller in Q2 2025 was Morgan Stanley, an estimated $353M sold.
Based on aggregated 13F filings for Q2 2025.